National Pension Service increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.5% during the 4th quarter, Holdings Channel reports. The firm owned 1,054,732 shares of the biopharmaceutical company’s stock after acquiring an additional 25,241 shares during the quarter. National Pension Service’s holdings in Gilead Sciences were worth $75,561,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Capital International Investors lifted its holdings in Gilead Sciences by 86.6% in the third quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock valued at $908,803,000 after buying an additional 5,205,983 shares during the period. Sanders Capital LLC acquired a new position in Gilead Sciences in the third quarter valued at approximately $427,585,000. Skandinaviska Enskilda Banken AB publ lifted its holdings in Gilead Sciences by 230.0% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 4,927,585 shares of the biopharmaceutical company’s stock valued at $399,233,000 after buying an additional 3,434,450 shares during the period. Renaissance Technologies LLC lifted its holdings in Gilead Sciences by 35.0% in the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock valued at $736,667,000 after buying an additional 2,700,600 shares during the period. Finally, Ameriprise Financial Inc. lifted its holdings in Gilead Sciences by 84.7% in the third quarter. Ameriprise Financial Inc. now owns 5,505,708 shares of the biopharmaceutical company’s stock valued at $446,197,000 after buying an additional 2,524,657 shares during the period. 75.71% of the stock is currently owned by institutional investors and hedge funds.
In related news, Chairman John C. Martin sold 50,000 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $83.56, for a total value of $4,178,000.00. Following the completion of the transaction, the chairman now owns 3,046,766 shares of the company’s stock, valued at $254,587,766.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $74.98, for a total transaction of $5,498,508.34. Following the completion of the transaction, the insider now directly owns 3,070,099 shares of the company’s stock, valued at approximately $230,196,023.02. The disclosure for this sale can be found here. In the last ninety days, insiders sold 418,333 shares of company stock valued at $32,742,108. 1.30% of the stock is owned by insiders.
Gilead Sciences, Inc. (NASDAQ GILD) opened at $80.70 on Monday. The firm has a market cap of $105,415.91, a price-to-earnings ratio of 9.45, a P/E/G ratio of -1.85 and a beta of 1.22. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $89.54. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.55 and a quick ratio of 3.48.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.11. The business had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm’s revenue for the quarter was down 18.7% compared to the same quarter last year. During the same quarter last year, the firm earned $2.70 earnings per share. equities analysts forecast that Gilead Sciences, Inc. will post 6.24 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be given a $0.57 dividend. The ex-dividend date is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a yield of 2.83%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio (DPR) is 59.77%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.